Comparative Pharmacology
Head-to-head clinical analysis: OXYCODONE HYDROCHLORIDE AND IBUPROFEN versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYCODONE HYDROCHLORIDE AND IBUPROFEN versus QDOLO.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Oxycodone: 3-5 hours; Ibuprofen: 1.8-2.5 hours. Clinical context: Oxycodone's half-life allows dosing every 4-6 hours; Ibuprofen's shorter half-life supports frequent dosing for sustained anti-inflammatory effect.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Oxycodone: primarily renal (87%) as metabolites, with ~19% unchanged; Ibuprofen: renal (90%) as metabolites, with ~10% unchanged; small biliary/fecal elimination for both.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist